You are here
Tyme Appoints Former Kite and Celgene Executive, Michele Korfin, as Chief Commercial Officer
NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies Inc, (Nasdaq: TYME), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today announced the appointment of former Kite Pharma and Celgene executive, Michele Korfin as the Company’s Chief Commercial Officer.
Ms. Korfin has over 20 years of experience in oncology, focused on product launches, oncology marketing strategy, commercial sales, market access and government affairs. Most recently at Kite Pharma, Ms. Korfin oversaw the market access strategy, including payer relations and reimbursement, for Yescarta®, the first approved CAR-T therapy in lymphoma. Prior to joining Kite, Ms. Korfin spent more than a decade at Celgene in a variety of key strategic and operational roles, including head of the oncology sales force and overseeing the global development programs for REVLIMID® in lymphoma and CLL. Ms. Korfin led Celgene’s oncology sales force of over 120 representatives, responsible for $650 million in revenue for ABRAXANE®, which is now a standard of care in pancreatic cancer.
“Ms. Korfin fills a critical role inside Tyme to integrate commercial and reimbursement planning into our late stage clinical trials,” said Steve Hoffman, CEO of Tyme. “Not only does she have broad experience in oncology, but deep expertise specific to commercialization of novel therapies from Kite and pancreatic cancer from Celgene.”
“There are many companies pursuing better solutions for cancer, but Tyme stood out to me,” said Ms. Korfin. “While I was at Kite, I saw first-hand how taking a novel approach can lead to dramatic shifts in patient outcomes. Tyme has not been afraid to re-evaluate how we approach cancer and I am proud to be a part of the team that is trying to redefine treatment for some of the most difficult cancers.”
Ms. Korfin has also held prior positions at Merck & Co as a manufacturing scientist, Bain & Company as a consultant and Schering-Plough in sales and marketing. Ms. Korfin holds an MBA from Harvard Business School and a B.S. in Pharmacy, summa cum laude, from Rutgers University. She is also on the Board of Trustees of BioNJ, the organization that represents the biotechnology industry for New Jersey.
Tyme Technologies, Inc., is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. For more information, visit www.tymeinc.com.
In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of Tyme's control. Factors that could cause actual results to differ materially from these forward-looking statements include the Company’s ability to successfully implement its clinical and other plans, competitive and regulatory developments, and the factors described in the section captioned “Risk Factors” of Tyme’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on June 13, 2018, as well as subsequent reports and filings from time to time with the SEC.
The information contained in this press release is as of release date and Tyme assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.